645 results on '"Teh, Bin Tean"'
Search Results
2. Single-cell landscape of idiopathic multicentric Castleman disease in identical twins
3. Abstract LT09: Integrative Multi-Omics Enhancer Activity Profiling Identifies Therapeutic Vulnerabilities in Cholangiocarcinoma of Different Etiologies
4. Spatially resolved niche and tumor microenvironmental alterations in gastric cancer peritoneal metastases
5. Biodiversity Medicine: New Horizon and New Opportunity for Cancer
6. Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches
7. Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer
8. Establishment and characterization of a patient-derived solitary fibrous tumor/hemangiopericytoma cell line model
9. Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies
10. Integrative Metabolomics, Genomics, and Transcriptomics Analysis Unravels Anti-Cancer Potential of Secondary Metabolites in Dillenia Suffruticosa
11. The prognostic value of CD39+CD8+ T cells as a potential surrogate marker of tumor-specific T cells in Asian triple-negative breast cancer
12. Establishment and characterization of a patient-derived solitary fibrous tumor/hemangiopericytoma cell line model
13. Contributors
14. Genetic and Epigenetic Alterations in Cancer
15. Abstract PR003: PBRM1-deficient PBAF complexes target aberrant genomic loci to activate NF-κB pathway in clear cell renal cell carcinoma
16. EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer
17. Lin28a maintains a subset of adult muscle stem cells in an embryonic-like state
18. Giant juvenile fibroadenomas with and without prominent pseudoangiomatous stromal hyperplasia (PASH)‐like change: clinicopathological and molecular characteristics
19. Muscle Injuries Induce a Prostacyclin‐PPAR γ /PGC1a‐FAO Spike That Boosts Regeneration
20. PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma
21. Abstract 1494: PBRM1-deficient PBAF complexes target de novo genomic loci to activate NF-κB pathway in clear cell renal cell carcinoma
22. Supplementary Figures 1-6 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
23. Data from VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma
24. Data from Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma
25. Tables S1-S16 from VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma
26. Supplementary Table 5 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
27. Supplementary Tables 1 through 13 from Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma
28. Supplementary Methods and Supplementary Figure and Table Legends from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
29. Supplementary Table 4 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
30. Tables S1-S16 from VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma
31. Figure S1-9; Supplementary methods from VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma
32. Supplementary Table 2 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
33. Supplementary Table 1 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
34. Data from Overexpression of Asparagine Synthetase and Matrix Metalloproteinase 19 Confers Cisplatin Sensitivity in Nasopharyngeal Carcinoma Cells
35. Supplementary Tables from Overexpression of Asparagine Synthetase and Matrix Metalloproteinase 19 Confers Cisplatin Sensitivity in Nasopharyngeal Carcinoma Cells
36. Supplementary Table 4 from Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma
37. Supplementary Table 4 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
38. Supplementary Table 3 from Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma
39. Data from Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma
40. Supplementary Table 2 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
41. Supplementary Table 3 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
42. Data from Overexpression of Asparagine Synthetase and Matrix Metalloproteinase 19 Confers Cisplatin Sensitivity in Nasopharyngeal Carcinoma Cells
43. Supplementary Table 4 from Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma
44. Supplementary Table 1 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
45. Supplementary Table 1 from Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma
46. Supplementary Figure 1 from Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma
47. Supplementary Text, Supplementary Figures 1 through 13, Supplementary Methods from Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma
48. Data from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
49. Supplementary Table 2 from Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma
50. Supplementary Figures 1-6 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.